Last update Dec. 4, 2020
Very Low Risk
Antiviral HIV protease inhibitor. Used and associated with ritonavir, in the treatment of HIV/AIDS.
It has been used experimentally in the treatment of the COVID-19 coronavirus (Li 2020, Lim 2020, SEFH 2020).
Oral administration in two daily doses.
Its pharmacokinetic data (moderately high molecular weight and very high percentage of protein binding) explain the negligible transfer into milk observed (Oumar 2018, Corbett 2014, Shapiro 2013, Palombi 2012).
The plasma levels of infants whose mothers took it were undetectable (Oumar 2018, Corbett 2014, Gandhi 2013, Shapiro 2013) or very low (Gandhi 2013, Shapiro 2013, Palombi 2012).
According to the policy adopted by the health authorities of each country, breastfeeding in mothers with HIV/AIDS may or may not be recommended.
With highly active antiretroviral therapy (HAART), the HIV viral load can be reduced to zero, reducing the risk of HIV transmission through breastfeeding to levels similar to those of formula feeding.
We do not have alternatives for Lopinavir since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM